真实世界美泊利单抗治疗重度哮喘:REALITI-A研究初步分析
REALITI-A是一项全球前瞻性观察性队列研究,纳入368例新处方美泊利单抗的重度哮喘患者,比较治疗前后临床显著急性发作率。结果显示临床显著急性发作率降低69%(从4.63降至1.43次/人年,p<0.001),需住院和/或急诊就诊的发作降低77%(从1.14降至0.27次/人年);159例有维持口服糖皮质激素剂量数据的患者中,中位日剂量从10.0 mg降至5.0 mg·day-1并维持至第53-56周,未报告新的安全性信号。
要点
- 美泊利单抗真实世界应用使临床显著急性发作率降低69%,需住院/急诊发作降低77%。
- 维持口服糖皮质激素中位日剂量从10.0 mg降至5.0 mg·day-1,并维持至第53-56周。
- 真实世界有效性与随机对照试验结果一致,未报告新的安全性信号。
核心结论
- 真实世界中美泊利单抗可显著减少重度哮喘患者临床显著急性发作和维持口服糖皮质激素剂量,有效性同临床试验结果一致。
研究设计与样本
- REALITI-A为全球、前瞻性、观察性队列研究,数据来自常规医疗访视。
- 纳入新处方美泊利单抗的重度哮喘患者,要求有美泊利单抗治疗前12个月相关病史(回顾性收集)。
- 初步分析纳入完成1年随访的早期起始者(截至2019年2月28日),共368例接受美泊利单抗治疗的患者。
主要发现
- 临床显著急性发作率(需口服糖皮质激素和/或住院和/或急诊就诊)从治疗前4.63次/人年降至随访期间1.43次/人年,降低69%(p<0.001)。
- 需住院和/或急诊就诊的急性发作率从1.14次/人年降至0.27次/人年,降低77%。
- 159例有治疗前维持口服糖皮质激素剂量数据的患者中,中位日剂量从治疗前10.0 mg降至随访第21-24周5.0 mg·day-1,并维持至第53-56周。
- 未报告新的安全性信号。
关键数值与推荐
- 临床显著急性发作率降低69%(4.63降至1.43次/人年,p<0.001)。
- 需住院和/或急诊就诊的急性发作率降低77%(1.14降至0.27次/人年)。
- 维持口服糖皮质激素中位日剂量从10.0 mg降至5.0 mg·day-1(第21-24周至第53-56周)。
临床怎么用
- 对于重度哮喘患者,美泊利单抗在真实临床实践中可显著减少急性发作和口服糖皮质激素维持剂量。
- 治疗决策可参考真实世界证据,其有效性与随机对照试验结果一致。
局限性
- 初步分析仅纳入完成1年随访的早期起始者,可能存在选择偏倚。
- 观察性研究设计,缺乏随机对照,可能存在混杂因素。
- 维持口服糖皮质激素剂量分析仅基于159例有可用数据的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, was demonstrated in randomised controlled trials; data on its real-world impact in routine clinical practice are starting to emerge. We assessed the effectiveness and safety of mepolizumab prescribed for patients in the real world. METHODS: REALITI-A is a global, prospective, observational cohort study, collecting data from routine healthcare visits from patients with asthma. Patients newly prescribed mepolizumab for severe asthma with 12 months of relevant medical history pre-mepolizumab (collected retrospectively) were enrolled. An initial analysis of data from early initiators who had completed 1 year of follow-up (as of February 28, 2019) was conducted. The primary objective was to compare the rate of clinically significant exacerbations (requiring oral corticosteroids (OCS) and/or hospitalisation and/or emergency department visit) before and after mepolizumab; exacerbations requiring hospitalisation and/or emergency department visit and change in maintenance OCS use were secondary objectives. Treatment-related adverse events were reported. RESULTS: Overall, 368 mepolizumab-treated patients were included. Rates of clinically significant exacerbations were reduced by 69% from 4.63 per person per year pre-treatment to 1.43 per person per year during follow-up (p<0.001), as were those requiring hospitalisation and/or emergency department visit (from 1.14 to 0.27 per person per year; 77% reduction). In 159 patients with maintenance OCS dose data available during the pre-treatment period, median daily dose decreased from 10.0 (pre-treatment) to 5.0 mg·day-1 by week 21-24 of follow-up, sustained until week 53-56. No new safety signals were reported. CONCLUSION: These data demonstrate that the effectiveness of mepolizumab is consistent with clinical trial results under real-world settings, with significant reductions in exacerbations and daily maintenance OCS dose.
引用
- Harrison T, Canonica GW, Chupp G, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020. PMID: 32817259. doi:10.1183/13993003.00151-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。